IL2 and neoplasm: NKTR-214 exposes tumors to a quantity of pegylated IL2 that is 500 times the amount of aldehyde-based interleukin and provides durable immunity against tumor re-stimulation in combination with anti-CTLA-4 antibodies (Charych et al., 2016).